Digital Health Market: Focus on Digital Therapeutics, Distribution by Type of Solution, Type of Therapy, Purpose of Solution, Type of Business Model, Target Therapeutic Area and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035

Table of Contents

1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1 Chapter Overview
3.2. Digitization in the Healthcare Sector
3.3. Next-Generation Healthcare Solutions
3.4. Key Concepts Associated with Digital Health Solutions
3.4.1. Cognitive Behavioral Therapy (CBT)
3.4.2. Internet of Things (IoT)
3.4.3. Big Data
3.4.4. Artificial Intelligence (AI)
3.4.5. Gamification
3.5. Overview of Digital Therapeutics
3.5.1. Key Strategic Initiatives
3.5.1.1. Digital Therapeutics Alliance (DTA)
3.5.1.2. Personal Connected Health (PCH) Alliance
3.5.1.3. Programs Initiated by The Centers for Disease Control and Prevention (CDC)
3.5.1.4. Health Insurance Portability and Accountability Act (HIPAA)
3.5.1.5. National Health Service (NHS) Guidelines
3.5.1.6. United States Food and Drug Administration (USFDA) Regulations for Digital Therapeutics
3.5.2. Typical Development and Commercialization Path for Digital Therapeutics
3.5.2.1. Discovery and Preclinical Phase
3.5.2.2. Clinical Trials and Validation
3.5.2.3. Negotiation Involving Insurance Providers / Payers
3.5.2.4. Distribution and Marketing
3.6 Concluding Remarks

4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Digital Therapeutics: Overall Market Landscape
4.2.1. Analysis by Status of Development
4.2.2. Analysis by Type of Solution
4.2.3. Analysis by Type of Therapy
4.2.4. Analysis by Purpose of Solution
4.2.5. Analysis by Target Indication
4.2.6. Analysis by Therapeutic Area
4.2.7. Analysis by Target Population
4.3. Digital Therapeutics: Additional Information
4.3.1. Analysis by Requirement of Prescription
4.3.2. Analysis by Duration of Course
4.3.3. Analysis by Cost of Solution
4.4. Digital Therapeutics: List of Developers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size
4.4.3. Analysis by Type of Business Model
4.4.4 Analysis by Location of Headquarters
4.5. Leading Developers: Analysis by Number of Digital Therapeutic Solutions
4.6. Leading Developers: Analysis by Portfolio Strength, Target Indication, and Company Size (4D Bubble Representation)
4.7. Analysis by Therapeutic Area and Company Size (Tree Map Representation)
4.8. Analysis of Regional Activity (World Map Representation)

5. PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions / Key Parameter
5.3. Methodology
5.4. Key Therapeutic Areas
5.4.1. Product Competitive Analysis: Digital Therapeutics Targeting Cardiovascular Disorders
5.4.2. Product Competitive Analysis: Digital Therapeutics Targeting Mental Health Problems
5.4.3. Product Competitive Analysis: Digital Therapeutics Targeting Metabolic Disorders
5.4.4. Product Competitive Analysis: Digital Therapeutics Targeting Neurological Disorders
5.4.5. Product Competitive Analysis: Digital Therapeutics Targeting Substance Use Disorders
5.4.6. Product Competitive Analysis: Digital Therapeutics Targeting Other Therapeutic Areas

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Akili Interactive
6.2.1 Company Overview
6.2.2. Product Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. Big Health
6.3.1. Company Overview
6.3.2. Product Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. dreem
6.4.1. Company Overview
6.4.2. Product Portfolio
6.4.3. Recent Developments and Future Outlook
6.5 Kaia Health
6.5.1. Company Overview
6.5.2. Product Portfolio
6.5.3. Recent Developments and Future Outlook
6.6. MindMaze
6.6.1. Company Overview
6.6.2. Product Portfolio
6.6.3. Recent Developments and Future Outlook
6.7. Omada Health
6.7.1. Company Overview
6.7.2. Product Portfolio
6.7.3. Recent Developments and Future Outlook
6.8. Pear Therapeutics
6.8.1. Company Overview
6.8.2. Product Portfolio
6.8.3 Recent Developments and Future Outlook
6.9. Vida Health
6.9.1. Company Overview
6.9.2. Product Portfolio
6.9.3. Recent Developments and Future Outlook
6.10. Voluntis
6.10.1. Company Overview
6.10.2. Product Portfolio
6.10.3. Recent Developments and Future Outlook
6.11. WellDoc
6.11.1. Company Overview
6.11.2. Product Portfolio
6.11.3. Recent Developments and Future Outlook
6.12. Wellthy Therapeutics
6.12.1. Company Overview
6.12.2. Product Portfolio
6.12.3. Recent Developments and Future Outlook

7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Digital Therapeutics: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Status
7.3.3. Analysis by Trial Registration Year and Trial Status
7.3.4. Analysis by Trial Phase
7.3.5. Analysis by Type of Study
7.3.6. Analysis by Study Design
7.3.7. Analysis by Study Age
7.3.8. Analysis by Gender of Patients
7.3.9. Analysis of Patients Enrolled by Trial Registration Year
7.3.10. Analysis by Type of Sponsor
7.3.11. Analysis by Focus Area
7.3.12. Analysis by Geography
7.3.13. Analysis by Trial Registration Year, Recruitment Status and Geography
7.3.14. Analysis of Patients Enrolled by Geography
7.4. Clinical End-Points Analysis

8. FUNDING AND INVESTMENT ANALYSIS
8.1. Chapter Overview
8.2. Type of Funding Models
8.3. Digital therapeutics: List of Funding and Investments
8.3.1 Analysis of Number of Funding Instances by Year of Establishment and Type of Funding
8.3.2. Analysis of Funding Instances by Year
8.3.3. Analysis of Amount Invested by Year
8.3.4. Analysis by Type of Funding
8.3.5. Analysis of Instances and Amount Invested by Type of Therapy
8.3.6. Analysis by Therapeutic Area
8.3.7. Analysis by Geography
8.3.8. Most Active Players: Analysis by Number of Instances
8.3.9. Most Active Players: Analysis by Amount Raised
8.3.10. Most Active Investors: Analysis by Number of Instances
8.4. Concluding Remarks

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Digital Therapeutics: List of Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.2.1. Analysis by Year of Partnership and Type of Partnership
9.3.2.2. Analysis by Type of Partnership and Company Size
9.3.3. Analysis by Type of Partner
9.3.3.1. Analysis by Year of Partnership and Type of Partner
9.3.3.2. Analysis by Type of Partnership and Type of Partner
9.3.3.3 Analysis by Type of Partner and Company Size
9.3.4. Analysis by Type of Therapy
9.3.4.1. Analysis by Type of Partnership and Type of Therapy
9.3.4.2. Analysis by Type of Partner and Type of Therapy
9.3.5. Analysis by Therapeutic Area
9.3.5.1. Analysis by Year of Partnership and Therapeutic Area
9.3.5.2 Analysis by Type of Partner and Therapeutic Area
9.3.6. Most Active Players: Analysis by Number of Partnerships
9.3.7. Analysis by Geography
9.3.8. Intercontinental and Intracontinental Agreements

10. GO-TO-MARKET STRATEGY
10.1. Chapter Overview
10.2. Marketing Strategies Adopted by Digital Therapeutic Developers
10.2.1. Participation in Global Events
10.2.2. Marketing on Social Media Platforms
10.2.3. Marketing on Online / Print Media Platforms
10.2.4. Undertaking Various Promotional Activities through Official Websites
10.2.5. Adoption of Different Business Models
10.2.5.1. B2C Business Model
10.2.5.2. B2B Business Model
10.2.5.2. B2B2C Business Model
10.2.6. Undertaking Various Promotional Activities through Product Add-ons
10.3. Concluding Remarks

11. BOWMAN CLOCK PRICING STRATEGY ANALYSIS
11.1. Chapter Overview
11.2. Bowman Strategy Clock
11.2.1. Two Dimensions of Bowman Strategy Clock
11.2.2. Eight Positions on Bowman Strategic Clock
11.3 Publisher Framework
11.3.1. Methodology
11.3.2. Theoretical Framework and Price Evaluation Hypothesis
11.3.3. Results and Interpretation
11.3.3.1. Product Price Evaluation Matrix: Based on Status of Development
11.3.3.2. Product Price Evaluation Matrix: Based on Type of Solution
11.3.3.3. Product Price Evaluation Matrix: Based on Purpose of Solution
11.3.3.4. Product Price Evaluation Matrix: Based on Type of Therapy
11.3.3.5. Product Price Evaluation Matrix: Based on Therapeutic Area
11.3.3.6. Product Price Evaluation Matrix: Based on Prescription Requirement
11.3.3.7. Product Price Evaluation Matrix: Based on Duration of Course
11.3.3.8. Product Price Evaluation Matrix: Based on Distribution Channel
11.4. Concluding Remarks

12. MARKET FORECAST
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Global Digital Therapeutics Market, 2022-2035
12.4. Digital Therapeutics Market: Analysis by Type of Solution, 2022-2035
12.4.1. Digital Therapeutics Market for Standalone Software Applications, 2022-2035
12.4.2. Digital Therapeutics Market for Combination Offerings focused on Software Application, Device and Personal Coach, 2022-2035
12.4.3. Digital Therapeutics Market for Combination Offerings focused on Software Application and Personal Coach, 2022-2035
12.4.4. Digital Therapeutics Market for Combination Offerings focused on Software Application and AI Support, 2022-2035
12.4.5. Digital Therapeutics Market for Combination Offerings focused on Software Application and Device), 2022-2035
12.4.6. Digital Therapeutics Market for Combination Offerings focused on Software Application, Device and AI Support), 2022-2035
12.4.7. Digital Therapeutics Market for Other Types of Solutions, 2022-2035
12.5. Digital Therapeutics Market: Analysis by Purpose of Solution, 2022-2035
12.5.1. Digital Therapeutics Market for Medication Replacement Solutions, 2022-2035
12.5.2. Digital Therapeutics Market for Medication Augmentation Solutions, 2022-2035
12.6. Digital Therapeutics Market: Analysis by Type of Therapy, 2022-2035
12.6.1 Digital Therapeutics Market for Curative Therapy, 2022-2035
12.6.2. Digital Therapeutics Market for Preventive Therapy, 2022-2035
12.7. Digital Therapeutics Market: Analysis by Business Model, 2022-2035
12.7.1. Digital Therapeutics Market for B2C Model, 2022-2035
12.7.2. Digital Therapeutics Market for B2B Model, 2022-2035
12.8. Digital Therapeutics Market: Analysis by Therapeutic Area, 2022-2035
12.8.1. Digital Therapeutics Market for Cardiovascular Disorders, 2022-2035
12.8.2. Digital Therapeutics Market for Chronic Pain, 2022-2035
12.8.3. Digital Therapeutics Market for Mental Health Problems, 2022-2035
12.8.4. Digital Therapeutics Market for Metabolic Disorders, 2022-2035
12.8.5. Digital Therapeutics Market for Neurological Disorders, 2022-2035
12.8.6. Digital Therapeutics Market for Respiratory Disorders, 2022-2035
12.8.7. Digital Therapeutics Market for Sleep Disorders, 2022-2035
12.8.8. Digital Therapeutics Market for Substance Use Disorders, 2022-2035
12.8.9. Digital Therapeutics Market for Other Disorders, 2022-2035
12.9. Digital Therapeutics Market: Analysis by Geography, 2022-2035
12.9.1. Digital Therapeutics Market in North America, 2022-2035
12.9.2. Digital Therapeutics Market in Europe, 2022-2035
12.9.3. Digital Therapeutics Market in Asia, 2022-2035
12.9.4. Digital Therapeutics Market in MENA, 2022-2035
12.9.5. Digital Therapeutics Market in Latin America, 2022-2035
12.9.6. Digital Therapeutics Market in Rest of the World, 2022-2035
12.10. Concluding Remarks

13. WOMEN DIGITAL HEALTH: AN EMERGING NEW CONCEPT
13.1. Introduction: Women Digital Health
13.2. Chapter Overview
13.3. Women’s Digital Health: Product Pipeline
13.3.1. Analysis by Type of Solution
13.3.2. Analysis by Status of Development
13.3.3. Analysis by Product Ratings
13.3.4. Analysis by Application Area
13.3.5. Analysis of Products by Different Stages of Pregnancy
13.3.6. Analysis by Purpose of Solution
13.3.7. Analysis by Type of End-Users
13.3.8. Analysis by Type of Solution and Application Area
13.4. Women’s Digital Health: Developer's Landscape
13.4.1. Analysis by Year of Establishment
13.4.2. Analysis by Company Size
13.4.3. Analysis by Location of Headquarters (Region-wise)
13.4.4. Analysis by Company Size and Region
13.4.5. Analysis by Location of Headquarters (Country-Wise)
13.4.6. Leading Players: Analysis by Number of Solutions
13.4.7. Regional Landscape: Analysis by Type of Solution

14. SWOT ANALYSIS
14.1. Chapter Overview
14.2. Comparison of SWOT Factors
14.2.1. Strengths
14.2.2. Weaknesses
14.2.3. Opportunities
14.2.4. Threats
14.2.5. Conclusion

15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. Ampersand Health
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Radhika Kamalia, Chief of Staffs to CEO and Strategy Lead
15.3. Canary Health
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Adam Kaufman, Ex-Chief Executive Officer
15.4. Dnurse Technology
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Cindy Zhang, Marketing Director
15.5. Embr Labs
15.5.1. Company Snapshot
15.5.2. Interview Transcript: Healther Ritchie, Chief Strategy Officer
15.6. Exosystems
15.6.1. Company Snapshot
15.6.2. Interview Transcript: Hooman Lee, Founder and Chief Executive Officer
15.7. Floreo
15.7.1. Company Snapshot
15.7.2. Interview Transcript: Vijay Ravindran, Chief Executive Officer
15.8. GAIA
15.8.1. Company Snapshot
15.8.2. Interview Transcript: Stan Sugarman, Chief Commercial Officer
15.9. Healios
15.9.1. Company Snapshot
15.9.2. Interview Transcript: Guilhem Dupnot , Founder and Chief Executive Officer
15.1 JOGGO Health
15.10.1. Company Snapshot
15.10.2. Interview Transcript: Siva Nadarajah, Co-Founder and President
15.11. metaMe Health
15.11.1. Company Snapshot
15.11.2 Interview Transcript: Tim Rudolphi, Chief Executive Officer
15.12. SelfBack
15.12.1. Company Snapshot
15.12.2. Interview Transcript: Soren Kleberg, Chief Executive Officer
15.13. Somatix
15.13.1. Company Snapshot
15.13.2. Interview Transcript: Eran Ofir, Ex-Chief Executive Officer
15.14. Tilak Healthcare
15.14.1. Company Snapshot
15.14.2. Interview Transcript: Edouard Gasser, Chief Executive Officer
15.15. Turnaround Health
15.15.1. Company Snapshot
15.15.2. Interview Transcript: Torin Block, Chief Executive Officer
15.16. Vida Health
15.16.1. Company Snapshot
15.16.2. Interview Transcript: Stephanie Tilenius, Co-Founder and Chief Executive Officer
15.17. Voluntis
15.17.1. Company Snapshot
15.17.2. Interview Transcript: Amelie Janson, Ex-Communication Manager
15.18. Wellthy Therapeutics
15.18.1. Company Snapshot
15.18.2. Interview Transcript: Palakh R Sarogi, Ex-Vice President Marketing, Arani Sarkra Ex-Senior Manager Consumer Marketing, and Yolande D’Mello, Ex-Marketing and Public Relations
15.19. Undisclosed
15.19.1. Interview Transcript: Anonymous, Founder and Chief Executive Officer

16. CONCLUDING REMARKS

17. APPENDIX 1: TABULATED DATA

18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures
Figure 3.1 Digital Health: Major Causes for Chronic Diseases
Figure 3.2 Historical Timeline of Digital Health: Analysis of Google Trends
Figure 3.3 Internet of Things: General Framework
Figure 3.4 Internet of Things: Applications in the Healthcare Sector
Figure 3.5 Prescription Digital Therapeutics: Process Map
Figure 3.6 Characteristics of a Digital Therapeutic Program: An Illustration
Figure 4.1 Digital Therapeutics: Distribution by Status of Development
Figure 4.2 Digital Therapeutics: Distribution by Type of Solution
Figure 4.3 Digital Therapeutics: Distribution by Type of Therapy
Figure 4.4 Digital Therapeutics: Distribution by Purpose of Solution
Figure 4.5 Digital Therapeutics: Distribution by Type of Therapy and Purpose of Solution
Figure 4.6 Digital Therapeutics: Distribution by Target Indication
Figure 4.7 Digital Therapeutics: Distribution by Therapeutic Area
Figure 4.8 Digital Therapeutics: Distribution by Target Population
Figure 4.9 Digital Therapeutic Solutions: Distribution by Prescription Requirements
Figure 4.10 Digital Therapeutic Solutions: Distribution by Duration of Course
Figure 4.11 Digital Therapeutic Solutions: Distribution by Cost of Solutions (USD)
Figure 4.12 Digital Therapeutic Developers: Distribution by Year of Establishment
Figure 4.13 Digital Therapeutics Developers: Distribution by Company Size
Figure 4.14 Digital Therapeutics Developers: Distribution by Business Model
Figure 4.15 Digital Therapeutics Developers: Distribution by Location of Headquarters
Figure 4.16 Leading Digital Therapeutics Developers: Distribution by Number of Digital Therapeutic Solutions
Figure 4.17 Leading Digital Therapeutics Developers: Distribution by Portfolio Strength, Therapeutic Area and Company Size (4-D Bubble Representation)
Figure 4.18 Digital Therapeutics: Distribution by Therapeutic Area and Company Size (Tree Map Representation)
Figure 4.19 Digital Therapeutics: Distribution of Regional Activity (World Map Representation)
Figure 5.1 Cardiovascular Disorders: Shift in Trends (2018-2023)
Figure 5.2 Product Competitiveness Analysis: Cardiovascular Disorders
Figure 5.3 Mental Health Problems: Shift in Trends (2018-2023)
Figure 5.4 Product Competitiveness Analysis: Mental Health Problems
Figure 5.5 Metabolic Disorders: Shift in Trends (2018-2023)
Figure 5.6 Product Competitiveness Analysis: Metabolic Disorders
Figure 5.7 Neurological Disorders: Shift in Trends (2018-2023)
Figure 5.8 Product Competitiveness Analysis: Neurological Disorders
Figure 5.9 Substance Use Disorders: Shift in Trends (2018-2023)
Figure 5.10 Product Competitiveness Analysis: Substance Use Disorders
Figure 5.11 Other Therapeutic Areas: Shift in Trends (2018-2023)
Figure 5.12 Product Competitiveness Analysis: Other Therapeutic Areas
Figure 6.1 Akili Interactive: Core Technologies and Benefits of Digital Products
Figure 6.2 Big Health: Digital Therapeutics Products and Clinical Trial Outcomes
Figure 6.3 WellDoc: Key Benefits of Diabetes Management Program
Figure 6.4 Wellthy Therapeutics: Diabetes Program
Figure 7.1 Key Methods to Validate Digital Therapeutic Solutions
Figure 7.2 Clinical Trial Analysis: Scope and Methodology
Figure 7.3 Clinical Trial Analysis: Cumulative Year-wise Trend of Trials by Trial Registration Year, Pre-2017-2022
Figure 7.4 Clinical Trial Analysis: Distribution by Trial Status
Figure 7.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 7.6 Clinical Trial Analysis: Distribution by Trial Phase
Figure 7.7 Clinical Trial Analysis: Distribution by Type of Study
Figure 7.8 Clinical Trial Analysis: Distribution by Study Design
Figure 7.9 Clinical Trial Analysis: Distribution by Study Age
Figure 7.10 Clinical Trial Analysis: Distribution by Gender of Patients
Figure 7.11 Clinical Trial Analysis: Distribution of Patient Enrolled by Trial Registration Year
Figure 7.12 Clinical Trial Analysis: Distribution by Type of Sponsor
Figure 7.13 Clinical Trial Analysis: Distribution by Focus Area
Figure 7.14 Clinical Trial Analysis: Distribution of Trials by Geography
Figure 7.15 Clinical Trial Analysis: Distribution by Trial Registration Year, Recruitment Status and Geography
Figure 7.16 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Figure 7.17 Clinical End-Points Analysis
Figure 7.18 Clinical Trials Analysis: Key Clinical End-Points for Metabolic Disorders
Figure 7.19 Clinical Trial Analysis: Primary and Secondary Clinical End-Points for Metabolic Disorders
Figure 8.1 Funding and Investment Analysis: Distribution of Instances by Year of Establishment and Type of Funding
Figure 8.2 Funding and Investment Analysis: Cumulative Year-wise Distribution of Instances, Pre-2019 - 2022
Figure 8.3 Funding and Investment Analysis: Cumulative Year-wise Distribution of Amount Invested, Pre-2019 - 2022 (USD Million)
Figure 8.4 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 8.5 Funding and Investment Analysis: Distribution of Instances by Year and Type of Funding, 2016 - 2022
Figure 8.6 Funding and Investment Analysis: Distribution of Amount Invested by Year and Type of Funding, 2016- 2022 (USD Million)
Figure 8.7 Funding and Investment Analysis: Summary of Amount Invested, 2016-2022
Figure 8.9 Funding and Investment Analysis: Distribution of Instances and Amount Invested by Type of Therapy (USD Million)
Figure 8.10 Funding and Investment Analysis: Distribution of Instances by Year and Type of Therapy, 2016 - 2022
Figure 8.11 Funding and Investment Analysis: Distribution of Amount Invested by Year and Type of Therapy, Pre-2019 - 2022 (USD Million)
Figure 8.12 Funding and Investment Analysis: Distribution of Instances by Therapeutic Area
Figure 8.13 Funding and Investment Analysis: Distribution of Amount Invested by Therapeutic Area (USD Million)
Figure 8.14 Funding and Investment Analysis: Distribution of Instances by Geography
Figure 8.15 Funding and Investment Analysis: Distribution of Amount Invested by Geography (USD Million)
Figure 8.16 Most Active Players: Distribution by Number of Instances
Figure 8.17 Most Active Players: Distribution by Amount Raised (USD Million)
Figure 8.18 Most Active Investors: Distribution by Number of Instances
Figure 8.19 Funding and Investment Summary, Pre-2019-2022 (USD Million)
Figure 9.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2016 - 2022
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Year-Wise Trend by Type of Partnership, Pre-2016 - 2022
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Figure 9.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 9.6 Partnerships and Collaborations: Year-Wise Trend by Type of Partner, Pre-2016 - 2022
Figure 9.7 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 9.8 Partnerships and Collaborations: Distribution by Type of Partner and Company Size
Figure 9.9 Partnerships and Collaborations: Distribution by Type of Therapy
Figure 9.10 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Therapy
Figure 9.11 Partnerships and Collaborations: Distribution by Type of Partner and Type of Therapy
Figure 9.12 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 9.13 Partnerships and Collaborations: Year-Wise Trend by Therapeutic Area
Figure 9.14 Partnerships and Collaborations: Distribution by Type of Partner and Therapeutic Area
Figure 9.15 Most Active Players: Distribution by Number of Partnerships
Figure 9.16 Partnerships and Collaborations: Regional Distribution
Figure 9.17 Partnerships and Collaborations: Country-Wise Distribution
Figure 9.18 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 10.1 Go-to-Market Strategy: Commonly Used Social Media Platforms
Figure 10.2 Go-to-Market Strategy: Online / Print Media Platforms
Figure 10.3 Go-to-Market Strategy: Promotional Activities through Official Websites
Figure 10.4 Go-to-Market Strategy: Adoption of Different Business Model
Figure 10.5 Go-to-Market Strategy: Promotional Activities through Product Websites
Figure 10.6 Go-to-Market Strategy: Key Marketing Strategies for New Entrants
Figure 10.7 Go-to-Market Strategy: Industry Stakeholder Opinions
Figure 11.1 Digital Therapeutics: Bowman Clock Pricing Strategy Matrix
Figure 11.2 Digital Therapeutics: Bowman Clock Pricing Strategy Graphical Interpretation
Figure 12.1 Overall Digital Therapeutics Market, 2022-2035 (USD Million)
Figure 12.2 Digital Therapeutics Market: Distribution by Type of Solution, 2022-2035 (USD Million)
Figure 12.3 Digital Therapeutics Market for Standalone Software Applications 2022-2035 (USD Million)
Figure 12.4 Digital Therapeutics Market for Combination Offerings of Software Application, Device and Personal Coach, 2022-2035 (USD Million)
Figure 12.5 Digital Therapeutics Market for Combination Offerings of Software Application and Personal Coach, 2022-2035 (USD Million)
Figure 12.6 Digital Therapeutics Market for Combination Offerings of Software Application and AI Support, 2022-2035 (USD Million)
Figure 12.7 Digital Therapeutics Market for Combination Offerings of Software Application and Device, 2022-2035 (USD Million)
Figure 12.8 Digital Therapeutics Market for Combination Offerings of Software Application, Device and AI Support, 2022-2035 (USD Million)
Figure 12.9 Digital Therapeutics Market for Other Types of Solutions, 2022-2035 (USD Million)
Figure 12.10 Digital Therapeutics Market: Distribution by Purpose of Solution, 2022-2035
Figure 12.11 Digital Therapeutics Market for Medication Replacement Solutions, 2022-2035 (USD Million)
Figure 12.12 Digital Therapeutics Market for Medication Augmentation Solutions, 2022-2035 (USD Million)
Figure 12.13 Digital Therapeutics Market: Distribution by Type of Therapy, 2022-2035 (USD Million)
Figure 12.14 Digital Therapeutics Market for Curative Therapies, 2022-2035 (USD Million)
Figure 12.15 Digital Therapeutics Market for Preventive Therapies, 2022-2035 (USD Million)
Figure 12.16 Digital Therapeutics Market: Distribution by Business Model, 2022-2035 (USD Million)
Figure 12.17 Digital Therapeutics Market for B2C Model, 2022-2035 (USD Million)
Figure 12.18 Digital Therapeutics Market for B2B Model, 2022-2035 (USD Million)
Figure 12.19 Digital Therapeutics Market: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Figure 12.20 Digital Therapeutics Market for Cardiovascular Disorders, 2022-2035 (USD Million)
Figure 12.21 Digital Therapeutics Market for Chronic Pain, 2022-2035 (USD Million)
Figure 12.22 Digital Therapeutics Market for Mental Health Problems, 2022-2035 (USD Million)
Figure 12.23 Digital Therapeutics Market for Metabolic Disorders, 2022-2035 (USD Million)
Figure 12.24 Digital Therapeutics Market for Neurological Disorders, 2022-2035 (USD Million)
Figure 12.25 Digital Therapeutics Market for Respiratory Disorders, 2022-2035 (USD Million)
Figure 12.26 Digital Therapeutics Market for Sleep Disorders 2022-2035 (USD Million)
Figure 12.27 Digital Therapeutics Market for Substance Use Disorders, 2022-2035 (USD Million)
Figure 12.28 Digital Therapeutics Market for Other Disorders, 2022-2035 (USD Million)
Figure 12.29 Digital Therapeutics Market: Distribution by Geography, 2022-2035 (USD Million)
Figure 12.30 Digital Therapeutics Market in North America, 2022-2035 (USD Million)
Figure 12.31 Digital Therapeutics Market in Europe, 2022-2035 (USD Million)
Figure 12.32 Digital Therapeutics Market in Asia, 2022-2035 (USD Million)
Figure 12.33 Digital Therapeutics Market in MENA, 2022-2035 (USD Million
Figure 12.34 Digital Therapeutics Market in Latin America, 2022-2035 (USD Million
Figure 12.35 Digital Therapeutics Market in Rest of the World, 2022-2035 (USD Million)
Figure 13.1 Women’s Digital Health: Distribution by Type of Solution
Figure 13.2 Women’s Digital Health: Distribution by Status of Development
Figure 13.3 Women’s Digital Health: Distribution by Product Ratings
Figure 13.4 Women’s Digital Health: Distribution by Application Area
Figure 13.5 Women’s Digital Health: Distribution of Products used during Stages of Pregnancy
Figure 13.6 Women’s Digital Health: Distribution by Purpose of Solution
Figure 13.7 Women’s Digital Health: Distribution by Type of End-Users
Figure 13.8 Women’s Digital Health: Distribution by Type of Solution and Application Area
Figure 13.9 Women’s Digital Health Developers: Distribution by Year of Establishment
Figure 13.10 Women’s Digital Health Developers: Distribution by Company Size
Figure 13.11 Women’s Digital Health Developers: Distribution by Location of Headquarters (Region-wise)
Figure 13.12 Women’s Digital Health Developers: Distribution by Company Size and Region
Figure 13.13 Women’s Digital Health Developers: Distribution by Location of Headquarters (Country-wise)
Figure 13.14 Leading Players: Distribution by Number of Solutions
Figure 13.15 Regional Landscape: Distribution by Type of Solution
Figure 14.1 Digital Therapeutics: Overview of SWOT Analysis
Figure 14.2 Comparison of SWOT Factors: Harvey Ball Analysis

List Of Tables
Table 4.1 Digital Therapeutics: Information on Status of Development and Launch Year
Table 4.2 Digital Therapeutics: Information on Type of Solution
Table 4.3 Digital Therapeutics: Information on Type of Therapy and Purpose of Solution
Table 4.4 Digital Therapeutics: Information on Target Indication(s), Therapeutic Area and Target Population
Table 4.5 Digital Therapeutic Solutions: Information on Prescription Requirement, Duration of Course and Cost of Solution
Table 4.6 Digital Therapeutics: List of Developers
Table 6.1 Digital Therapeutics: List of Companies Profiled
Table 6.2 Akili Interactive: Company Snapshot
Table 6.3 Akili Interactive: Digital Therapeutic Solutions Portfolio
Table 6.4 Akili Interactive: Recent Developments and Future Outlook
Table 6.5 Big Health: Company Snapshot
Table 6.6 Big Health: Digital Therapeutic Solutions Portfolio
Table 6.7 Big Health: Recent Developments and Future Outlook
Table 6.8 dreem: Company Snapshot
Table 6.9 dreem: Digital Therapeutic Solutions Portfolio
Table 6.10 dreem: Recent Developments and Future Outlook
Table 6.11 Kaia Health: Company Snapshot
Table 6.12 Kaia Health: Digital Therapeutic Solutions Portfolio
Table 6.13 Kaia Health: Recent Developments and Future Outlook
Table 6.14 MindMaze: Company Snapshot
Table 6.15 MindMaze: Digital Therapeutic Solutions Portfolio
Table 6.16 MindMaze: Recent Developments and Future Outlook
Table 6.17 Omada Health: Company Snapshot
Table 6.18 Omada Health: Digital Therapeutic Solutions Portfolio
Table 6.19 Omada Health: Recent Developments and Future Outlook
Table 6.20 Pear Therapeutics: Company Snapshot
Table 6.21 Pear Therapeutics: Digital Therapeutic Solutions Portfolio
Table 6.22 Pear Therapeutics: Recent Developments and Future Outlook
Table 6.23 Vida Health: Company Snapshot
Table 6.24 Vida Health: Digital Therapeutic Solutions Portfolio
Table 6.25 Vida Health: Recent Developments and Future Outlook
Table 6.26 Voluntis: Company Snapshot
Table 6.27 Voluntis: Digital Therapeutic Solutions Portfolio
Table 6.28 Voluntis: Recent Developments and Future Outlook
Table 6.29 WellDoc: Company Snapshot
Table 6.30 WellDoc: Digital Therapeutic Solutions Portfolio
Table 6.31 WellDoc: Recent Developments and Future Outlook
Table 6.32 Wellthy Therapeutics: Company Snapshot
Table 6.33 Wellthy Therapeutics: Digital Therapeutic Solutions Portfolio
Table 6.34 Wellthy Therapeutics: Recent Developments and Future Outlook
Table 8.1 Digital Therapeutics: Funding and Investments, Information on Year of Investment, Type of Funding, Amount Invested and Investor(s), 2016 - 2022
Table 8.2 Digital Therapeutics: Funding and Investments, Information on Year of Establishment, Location of Headquarters of Recipients, Type of Therapy and Therapeutic Area
Table 9.1 Digital Therapeutics: List of Collaborations
Table 9.2 Digital Therapeutics: Partnerships and Collaborations, Information on Type of Agreement (Region-wise and Geography-wise)
Table 10.1 Digital Therapeutics: Summary of Marketing Strategies
Table 10.2 Go-to-Market Strategy: Product Specific Websites
Table 11.1 Product Price Evaluation Matrix: Based on Status of Development
Table 11.2 Product Price Evaluation Matrix: Based on Type of Solution
Table 11.3 Product Price Evaluation Matrix: Based on Purpose of Solution
Table 11.4 Product Price Evaluation Matrix: Based on Type of Therapy
Table 11.5 Product Price Evaluation Matrix: Based on Therapeutic Area
Table 11.6 Product Price Evaluation Matrix: Based on Prescription Requirement
Table 11.7 Product Price Evaluation Matrix: Based on Duration of Course
Table 11.8 Product Price Evaluation Matrix: Based on Distribution Channel
Table 15.1 Company Snapshot: Ampersand Health
Table 15.2 Company Snapshot: Canary Health
Table 15.3 Company Snapshot: Dnurse Technology
Table 15.4 Company Snapshot: Embr Labs
Table 15.5 Company Snapshot: Exosystems
Table 15.6 Company Snapshot: Floreo
Table 15.7 Company Snapshot: GAIA
Table 15.8 Company Snapshot: Healios
Table 15.9 Company Snapshot: JOGGO Health
Table 15.10 Company Snapshot: metaMe Health
Table 15.11 Company Snapshot: SelfBack
Table 15.12 Company Snapshot: Somatix
Table 15.13 Company Snapshot: Tilak Healthcare
Table 15.14 Company Snapshot: Turnaround Health
Table 15.15 Company Snapshot: Vida Health
Table 15.16 Company Snapshot: Voluntis
Table 15.17 Company Snapshot: Wellthy Therapeutics
Table 17.1 Digital Therapeutics: Distribution by Status of Development
Table 17.2 Digital Therapeutics: Distribution by Type of Solution
Table 17.3 Digital Therapeutics: Distribution by Type of Therapy
Table 17.4 Digital Therapeutics: Distribution by Purpose of Solution
Table 17.5 Digital Therapeutics: Distribution by Type of Therapy and Purpose of Solution
Table 17.6 Digital Therapeutics: Distribution by Target Indication(s)
Table 17.7 Digital Therapeutics: Distribution by Therapeutic Area
Table 17.8 Digital Therapeutics: Distribution by Target Population
Table 17.9 Digital Therapeutics: Distribution by Prescription Requirement
Table 17.10 Digital Therapeutics: Distribution by Duration of Course
Table 17.11 Digital Therapeutics: Distribution by Cost of Solution (USD)
Table 17.12 Digital Therapeutics Developers: Distribution by Year of Establishment
Table 17.13 Digital Therapeutics Developers: Distribution by Company Size
Table 17.14 Digital Therapeutics Developers: Distribution by Business Model
Table 17.15 Digital Therapeutics Developers: Distribution by Location of Headquarters
Table 17.16 Leading Digital Therapeutics Developers: Distribution by Number of Digital Therapeutics Solutions
Table 17.17 Leading Digital Therapeutics Developers: Distribution by Portfolio Strength, Therapeutic Area and Company Size (4-D Bubble Representation)
Table 17.18 Digital Therapeutics: Distribution by Therapeutic Area and Company Size (Tree Map Representation)
Table 17.19 Digital Therapeutics: Distribution by Regional Activity
Table 17.20 Cardiovascular Disorders: Shift in Trends (2018 - 2023)
Table 17.21 Mental Health Problems: Shift in Trends (2018 - 2023)
Table 17.22 Metabolic Disorders: Shift in Trends (2018 - 2023)
Table 17.23 Neurological Disorders: Shift in Trends (2018 - 2023)
Table 17.24 Substance Use Disorders: Shift in Trends (2018 - 2023)
Table 17.25 Other Therapeutic Areas: Shift in Trends (2018 - 2023)
Table 17.26 Clinical Trial Analysis: Scope and Methodology
Table 17.27 Clinical Trial Analysis: Cumulative Year-wise Trend of Trials by Trial Registration Year, Pre-2017-2022
Table 17.28 Clinical Trial Analysis: Distribution by Trial Status
Table 17.29 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 17.30 Clinical Trial Analysis: Distribution by Trial Phase
Table 17.31 Clinical Trial Analysis: Distribution by Type of Study
Table 17.32 Clinical Trial Analysis: Distribution by Study Design
Table 17.33 Clinical Trial Analysis: Distribution by Study Age
Table 17.34 Clinical Trial Analysis: Distribution by Gender of Patients
Table 17.35 Clinical Trial Analysis: Distribution of Patient Enrolled by Trial Registration Year
Table 17.36 Clinical Trial Analysis: Distribution by Type of Sponsor
Table 17.37 Clinical Trial Analysis: Distribution by Focus Area
Table 17.38 Clinical Trial Analysis: Distribution of Trials by Geography
Table 17.39 Clinical Trial Analysis: Distribution by Trial Registration Year, Recruitment Status and Geography
Table 17.40 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Table 17.41 Clinical End-Points Analysis
Table 17.42 Clinical Trials Analysis: Key Clinical End-Points for Metabolic Disorders
Table 17.43 Clinical Trial Analysis: Primary and Secondary Clinical End-Points for Metabolic Disorders
Table 17.44 Funding and Investment Analysis: Distribution of Instances by Year of Establishment and Type of Funding
Table 17.45 Funding and Investment Analysis: Cumulative Year-wise Distribution of Instances, Pre-2019 - 2022
Table 17.46 Funding and Investment Analysis: Cumulative Year-wise Distribution of Amount Invested, Pre-2019 - 2022 (USD Million)
Table 17.47 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Table 17.48 Funding and Investment Analysis: Distribution of Instances by Year and Type of Funding, 2016 - 2022
Table 17.49 Funding and Investment Analysis: Distribution of Amount Invested by Year and Type of Funding, 2016- 2022 (USD Million)
Table 17.50 Funding and Investment Analysis: Summary of Amount Invested, 2016-2022
Table 17.51 Funding and Investment Analysis: Distribution of Instances and Amount Invested by Type of Therapy (USD Million)
Table 17.52 Funding and Investment Analysis: Distribution of Instances by Year and Type of Therapy, 2016 - 2022
Table 17.53 Funding and Investment Analysis: Distribution of Amount Invested by Year and Type of Therapy, Pre-2019 - 2022 (USD Million)
Table 17.54 Funding and Investment Analysis: Distribution of Instances by Therapeutic Area
Table 17.55 Funding and Investment Analysis: Distribution of Amount Invested by Therapeutic Area (USD Million)
Table 17.56 Funding and Investment Analysis: Distribution of Instances by Geography
Table 17.57 Funding and Investment Analysis: Distribution of Amount Invested by Geography (USD Million)
Table 17.58 Most Active Players: Distribution by Number of Instances
Table 17.59 Most Active Players: Distribution by Amount Raised (USD Million)
Table 17.60 Most Active Investors: Distribution by Number of Instances
Table 17.61 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2016-2022
Table 17.62 Partnerships and Collaborations: Distribution by Type of Partnership
Table 17.63 Partnerships and Collaborations: Year-Wise Trend by Type of Partnership, Pre-2016-2022
Table 17.64 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Table 17.65 Partnerships and Collaborations: Distribution by Type of Partner
Table 17.66 Partnerships and Collaborations: Year-Wise Trend by Type of Partner, Pre-2016-2022
Table 17.67 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 17.68 Partnerships and Collaborations: Distribution by Type of Partner and Company Size
Table 17.69 Partnerships and Collaborations: Distribution by Type of Therapy
Table 17.70 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Therapy
Table 17.71 Partnerships and Collaborations: Distribution by Type of Partner and Type of Therapy
Table 17.72 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 17.73 Partnerships and Collaborations: Year-Wise Trend by Therapeutic Area
Table 17.74 Partnerships and Collaborations: Distribution by Type of Partner and Therapeutic Area
Table 17.75 Most Active Players: Distribution by Number of Partnerships
Table 17.76 Partnerships and Collaborations: Regional Distribution
Table 17.77 Partnerships and Collaborations: Country-Wise Distribution
Table 17.78 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 17.79 Go-to-Market Strategy: Commonly Used Social Media Platforms
Table 17.80 Go-to-Market Strategy: Online / Print Media Platforms
Table 17.81 Go-to-Market Strategy: Promotional Activities through Official Websites
Table 17.82 Go-to-Market Strategy: Adoption of Different Business Model
Table 17.83 Go-to-Market Strategy: Promotional Activities through Product Websites
Table 17.84 Overall Digital Therapeutics Market, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.85 Digital Therapeutics Market: Distribution by Type of Solution, 2022-2035 (USD Million)
Table 17.86 Digital Therapeutics Market for Standalone Software Applications, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.87 Digital Therapeutics Market for Combination Offerings of Software Application, Device and Personal Coach, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.88 Digital Therapeutics Market for Combination Offerings of Software Application and Personal Coach, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.89 Digital Therapeutics Market for Combination Offerings of Software Application and AI Support, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.90 Digital Therapeutics Market for Combination Offerings of Software Application and Device, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.91 Digital Therapeutics Market for Combination Offerings of Software Application, Device and AI Support, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.92 Digital Therapeutics Market for Other Type of Solutions, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.93 Digital Therapeutics Market: Distribution by Purpose of Solution, 2022-2035 (USD Million)
Table 17.94 Digital Therapeutics Market for Medication Replacement Solutions, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.95 Digital Therapeutics Market for Medication Augmentation Solutions, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.96 Global Digital Therapeutics Market: Distribution by Type of Therapy, 2022 and 2035 (USD Million)
Table 17.97 Digital Therapeutics Market for Curative Therapy, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.98 Digital Therapeutics Market for Preventive Therapy, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.99 Global Digital Therapeutics Market: Distribution by Business Model, 2022-2035 (USD Million)
Table 17.100 Digital Therapeutics Market for B2C Model, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.101 Digital Therapeutics Market for B2B Model, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.102 Global Digital Therapeutics Market: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Table 17.103 Digital Therapeutics Market for Cardiovascular Disorders, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.104 Digital Therapeutics Market for Chronic Pain, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.105 Digital Therapeutics Market for Mental Health Problems, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.106 Digital Therapeutics Market for Metabolic Disorders, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.107 Digital Therapeutics Market for Neurological Disorders, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.108 Digital Therapeutics Market for Respiratory Disorders, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.109 Digital Therapeutics Market for Sleep Disorders, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.110 Digital Therapeutics Market for Substance Use Disorders, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.111 Digital Therapeutics Market for Other Disorders, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.112 Global Digital Therapeutics Market: Distribution by Geography, 2022 and 2035
Table 17.113 Digital Therapeutics Market in North America, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.114 Digital Therapeutics Market in Europe, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.115 Digital Therapeutics Market in Asia, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.116 Digital Therapeutics Market in MENA, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.117 Digital Therapeutics Market in Latin America, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.118 Digital Therapeutics Market in Rest of the World, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Million)
Table 17.119 Women’s Digital Health: Distribution by Type of Solution
Table 17.120 Women’s Digital Health: Distribution by Status of Development
Table 17.121 Women’s Digital Health: Distribution by Product Ratings
Table 17.122 Women’s Digital Health: Distribution by Application Area
Table 17.123 Women’s Digital Health: Distribution by Products Usage with respect to Pregnancy
Table 17.124 Women’s Digital Health: Distribution by Purpose of Solution
Table 17.125 Women’s Digital Health: Distribution by Type of End-Users
Table 17.126 Women’s Digital Health: Distribution by Type of Solution and Application Area
Table 17.127 Women’s Digital Health Developers: Distribution by Year of Establishment
Table 17.128 Women’s Digital Health Developers: Distribution by Company Size
Table 17.129 Women’s Digital Health Developers: Distribution by Location of Headquarters (Region-wise)
Table 17.130 Women’s Digital Health Developers: Distribution by Company Size and Region
Table 17.131 Women’s Digital Health Developers: Distribution by Location of Headquarters (Country-wise)
Table 17.132 Leading Players: Distribution by Number of Solutions
Table 17.133 Regional Landscape: Distribution by Type of Solution

Companies Mentioned

• 2048 Ventures
• 23andMe
• 2breathe Technologies
• 2Morrow
• 3L Capital
• 3M Ventures
• 3VC
• 4FO Ventures
• 4point0
• 500 Startups
• 5AM Ventures
• 7wire Ventures
• 8VC
• 98point6
• 9Unicorns
• A Better Weigh
• A-Round Capital
• a thousand colibris  
• A195 Capital
• Aavia
• Ababax Health
• Abbott
• AbbVie
• AbleTo
• Accel
• Acceleration Partners
• Accelmed Partners 
• Accolade
• Act Venture Capital
• Aculys Pharma 
• Advance Venture Partners
• Advanced Circulatory Systems
• Advanced Maternity Innovations
• Advantage Capital
• Advantage Consumer Healthcare
• Aequus Pharmaceuticals
• Aetna
• Aflac Corporate Ventures
• AH Warren Trust
• AI Fund
• AIA Group
• AIB Seed Capital Fund
• Aindra Systems
• Airbus
• Akili Interactive
• Akilia Partners
• Al-Ahli Hospital
• Albion Capital
• AlbionVC
• Alex Therapeutics
• Alfvén & Didriksson
• Alife Health
• Alkeon Capital Management
• Allara Health
• Allen & Company
• A.G.P./ Alliance Global Partners
• Allianz Partners
• Ally Bridge Group
• Allysian Sciences
• Almirall
• Alpha Femtech
• Alsace Business Angels
• AltaIR Capital
• Althea Group 
• Altitude Ventures
• Altoida
• Alumni Ventures
• Amadeus Capital Partners
• Amalgam
• Amar Seva Sangam
• Amara Therapeutics
• Amazon Smbhav Venture Fund
• Amazon Web Service (AWS)
• Amboy Street Ventures
• AME Cloud Ventures
• Amelia
• American Association of Diabetes Educators
• American Diabetes Association
• Intermountain Healthcare
• American Investment Holdings
• American Stroke Association
• Amgen Ventures
• Amiko
• aMoon
• Ampersand Health
• Amplify Capital
• Ananda Impact Ventures.
• Anastasia Kovba
• Anchorless Bangladesh
• Ancora Finance Group
• Andera Partners
• Andreessen Horowitz
• AngelList
• Anorak Ventures
• Anthem
• Anthemis Exponential Ventures
• Anthemis
• AOA Dx
• Aphelion Capital
• AppBasic
• Appalachian Regional Healthcare
• AppliedVR
• Apricity
• Apricity Health
• Aptar
• Aptar Pharma
• Arbor Health
• Arboretum Ventures
• Ardea Partners
• ArlanWasHere Investments
• ArrowMark Partners
• Artesian
• Arthritis New Zealand
• Asabys Partners
• Asahi Kasei Corporate Ventures Capital
• Ascensia Diabetes Care
• Ascension Brighton Center for Recovery
• Ascension Ventures
• Aspect Ventures
• Aspivix
• Asset Management Ventures
• Astellas Pharma
• Astinno
• AT&T
• Athena Feminine Technologies
• Atheneum 
• Atlantic Labs
• Atlantic Therapeutics
• AtlasV Global
• ATMA Journey Centers
• Atomico
• ATX Therapeutics
• Australasian College of Behavioural Optometrists (ACBO)
• Autism Impact Fund
• Autism Learning Partners
• Autonomous Open Innovation (AOI)
• Ava Women (Acquired by FemTec)
• Avaana Capital
• Avestria Ventures
• Aviva Ventures
• Avricore Health
• Awakn Life Sciences
• Awesome People Ventures
• AXA
• AXA Venture Partners (AVP)
• Axia Women’s Health
• B Capital Group
• Baby2Body
• Babyscripts
• Backstage Capital
• Baillie Gifford
• balance-app
• Balderton Capital
• Banner|Aetna
• Baseline Ventures
• Bayer
• Bayer G4A
• BBG Ventures
• BlueCross BlueShield Venture Partners
• Beats Medical
• Beaumont Hospital
• BeCareLink
• Beehive Holdings
• BEENEXT 
• BehaVR
• Bellabeat
• Beneufit
• Bertelsmann India Investments
• Bessemer Venture Partners
• Bethnal Green Ventures
• Better Therapeutics
• Bettermeant Health
• Beyond Next Ventures
• BGF
• Bia Med
• Big Health
• Bill Lucia
• Bimark
• Biocon
• BIOCORP
• Biofourmis
• Biogen
• Biomedix
• BioTrak Therapeutics
• Biovotion
• BIXINK Therapeutics
• BJC Healthcare
• Blackbird Ventures
• Blackstone Growth
• Blessing Health System
• bLife
• Bliss Digital Therapeutics
• Bloom Burton & Co
• Bloomer Tech
• Bloomlife
• Bloomth
• Blossom Capital
• Blue Cross and Blue Shield of Kansas City (Blue KC)
• Blue Cross Blue Shield of Arizona
• Blue Cross Blue Shield of Massachusetts
• Blue Cross Blue Shield of Michigan
• Blue Cross Blue Shield Venture Partners
• Blue Mesa Health
• Blue Note Therapeutics
• Blue Ox Healthcare Partners
• Blue Shield of California
• Blue Water Life Science Fund
• Blueprint Health
• BlueRun Ventures
• BOC Healthcare
• Boehringer Ingelheim
• Boehringer Ingelheim Venture Fund
• Bold Capital Partners
• Bold Health
• Bolt Ventures
• Bonit Capital
• Bonnier Ventures
• Bonzun
• Borski Fund
• Bose Ventures
• Boston Medical Center
• Bpifrance
• Brain Power
• Brain+
• BrainFx
• Braster
• Breastlink
• BreezoMeter
• Bridge Bank
• Bridge Builders Collaborative
• Bridge Health Medical
• BridgeHealth
• BrightCap Ventures
• Brilliantly Warm
• Bristol-Myers Squibb
• Brooklands Capital Strategies
• btov Partners
• Buoy Health
• Burst IQ
• Business Health Care Group
• B-wom
• Cabin VC
• Caffeinated Capital
• Caixa Capital Risc
• Calpro AS
• Cambridge Design Partnership
• Cambridge Digital Health
• Cambridge Femtech Society
• Canaan Partners
• Canary Health
• Cancer Institute Hospital of JFCR 
• Candlelit Therapy
• Canepa Advanced Healthcare Fund
• Canopie
• Canvas Ventures
• Capier Investments
• capital300
• Cara Care
• Carbomed Medical Solutions
• CardioRenal
• Care4Cute
• CareFirst
• CareLinx
• CareSignal
• CAREvolution
• Carlyle
• Carrot & Company
• Carrot Health (Acquired by Unite Us)
• Carrum Health
• CASA SEAT
• Casdin Capital
• Castlight Health
• Catasys
• Cayaba Care
• Cedars-Sinai Medical Center
• Celebrate the Children
• Centene Corporation
• Cerner Corporation
• CerpassRx
• CES Unveiled
• CG Ventures
• Charles River Ventures
• CheckUp & Choices
• Chiaroscuro Foundation
• Chibagin Capital
• Chiesi 
• Children’s Community Health Plan
• Children’s Hospital of Philadelphia
• Chorus Community Health Plans
• Chopra Foundation
• Chorus Health
• Chugai Pharmaceutical
• Cigna
• Cigna Ventures
• Cipla
• City Light Capital
• Civilization Ventures
• Claritas Health Ventures
• Clarkson University
• Clementine app
• Click Therapeutics
• CLSA
• Clue by Biowink
• CogniFit
• Cognoa
• Collaborative Fund
• Collective Health
• COLOPL VR Fund
• Community Health Network of Connecticut.
• Companion Medical
• Company K Partners
• Company Ventures
• Competitive Health
• Comprehensive Pain Specialists
• Concord Health Partners
• Conference Series
• Connors Center 
• Consortium Health Plans
• CoreHealth Technologies
• Cority
• Coroflo
• Correlation Ventures
• Cortado Ventures
• Costco Wholesale
• Council For Trade and Investment Promotion (CTIP)
• Cowen Private Investments
• COYA Partners
• CRCM Ventures
• Creandum
• Creas Impacto
• Creative Destruction Lab
• Crescent Ridge Partners
• Crimsonox Capital
• Crista Galli Ventures
• Crohn's & Colitis Foundation
• Crossroads Treatment Centers
• Curavit Clinical Research
• CureApp
• Curebase
• Curio Digital Therapeutics
• Currae Healthtech Fund
• Toyoshima CVC
• CVS Health Ventures
• Cyberdine
• dacadoo
• Dai-ichi Life
• DAK Gesundheit 
• Dario Health
• Dartmouth College
• Dayzz
• Debiopharm
• Deerfield Management 
• Delivering Scientific Innovation for Autism
• Deloitte
• Dendera Ventures
• United States Department of Defense 
• United States Department of Veteran Affairs
• Development Bank of Wales
• Dexcom
• Dexium Technologies
• DFJ Growth
• Danish Diabetes Association
• Diabnext (Acquired by Glooko)
• Diasend
• Digbi Health
• DG Daiwa Ventures
• Digital Health Acquisition 
• Digital Health Today
• Digithera
• DigiTx Partners
• Dignity Health
• DN Capital
• Dnurse Technology
• Doctor on Demand
• Doha Tech Angels
• Dopavision
• Double Peak 
• Downing Ventures
• Dragoneer Investment
• Draper Esprit and Touchstone Innovations
• DrChrono
• Dream Incubator
• Dreamit Ventures
• Dreem
• Driehaus Capital Management
• Droobi Health
• dTHx
• Duke University School of Medicine
• Duopharma Biotech Berhad
• e&
• Ease Healthcare
• Echo Health Ventures
• eClinicalHealth
• Eco-Fusion
• EDBI
• Eden Strategy Institute
• Efficient Capacity Fund
• Ehave
• EHE Health
• Ei.Ventures
• Eisai
• EIT Health
• ElaWoman
• Elda Health
• Electronics and Telecommunication Research Institute (ETRI)
• Elevance Health
• Eli Health
• Eli Lilly
• Elidah
• Ellerca Health
• EloCare
• Elvie
• Elysium Venture Capital
• Embr Labs
• Emme
• Emotional Intelligence Ventures
• Endeavor Catalyst
• Endeavour Vision
• Endodiag
• Endometrix
• ENDRA Life Sciences
• Enovis
• Enso (Acquired by Hinge Health)
• Enterprise Ireland
• Enterprise Ireland Commercialisation Fund
• Entreé Capital
• Enzia Ventures
• EQT Ventures
• eQventure
• Ermua City Council
• Eurazeo
• European Commission
• European Innovation Council
• European Innovation Council and SMEs Executive Agency (EISMEA)
• Eurostars
• Evernorth’s Health 
• Evernow
• EVERSANA
• EvidentIQ
• Evidity Health Capital
• Exandus
• Exosystems
• Expon Capital
• Express Script
• Faegre Drinker
• Fairhaven Health
• Farallon Capital Management
• Fearless Ventures
• Feel Therapeutics
• Felicis Ventures
• Femasys
• FemCy
• FEMM
• Femna Health
• Femometer
• FemTec Healthcare
• FemTech Analytics
• FemTech Focus
• FemX
• Fenbushi Capital
• Ferne
• Ferrer
• Fertility Focus
• FetoLife
• Fidelity Management and Research Company
• Fifty Years
• FinTLV Ventures
• Finnish Student Health System (FSHS)
• Fireside Ventures
• First Nation Group
• First Round Capital
• FirstCheck Africa
• FirstMark Capital
• Fish & Richardson
• Fit4D
• Fitterfly
• Fizimed
• Flare Capital Partners
• Flint Capital
• Flo Health
• Flöka
• Floreo
• Florida Hospital
• Flying Health
• FMZ Ventures
• Fondation pour l'Innovation Technologique (FIT)
• Fontys Hogeschool ICT
• Ford Motor Company
• Forerunner Ventures
• Foresight Group
• Forth Management
• Fortunis Capital
• Founder Institute
• Founders Fund
• Foundry Group
• F-Prime Capital
• Frame Fertility
• Franklin Templeton
• Fred Hutchinson Cancer Research Center
• Freespira
• Freestyle Capital
• Frist Center for Autism and Innovation
• Frontier Venture Capital
• Frost & Sullivan
• Frøya Life
• Fruit Street 
• Frumtak Ventures
• Fuel Ventures
• Future\Perfect Ventures
• Future Positive Capital
• FWD Takaful
• GAIA
• Gaido Health (Acquired by Biofourmis)
• Gaingels
• Gallagher Student Health & Special Risk
• Gals Bio
• Games for Health
• Garmin
• gBETA Medtech
• GC VR Tracker Fund
• Gedeon Richter
• Gelt Venture Capital
• General Atlantic
• General Catalyst
• General Catalyst 
• Genesis Ventures
• Gennev
• Genoa Telepsychiatry
• Georgian
• Giant Leap
• Gilde Healthcare
• Ginger
• GingerBread Capital
• GlaxoSmithKline
• Global Brain 
• Global Founders Capital
• GlobalYeast
• Glooko
• Glow Inc
• Golden Seeds
• Google
• Grand Central Tech
• Great Heights Family Medicine
• Green Shield Canada
• Greycroft
• GrowX Ventures
• Grupo Fleury
• GSK NEXT
• GSR Ventures
• GuideWell Mutual Holding Corporation
• gumi Cryptos Capital (gCC)
• GV
• H.I.G. BioHealth Partners
• Hackster.io
• Hadean Ventures
• Halza
• Hambrecht Ducera Growth Ventures
• Hannover Re US
• Happify Health
• Harvard Business School Association of Northern California (HBSANC)
• Harvard Medical School
• Harvard University
• HAX
• Haxus
• Headspace
• Healios
• Health & Her
• Health Allliance Plan
• Health Catalyst
• Health Catalyst Capital
• Health Enterprise Partners (HEP)
• Health in Her HUE
• Healthmine
• Health Transformation Alliance
• HealthCap
• Healthcare Innovation Fund
• Health Inn
• HealthPartners
• HealthXL
• Healthy Trucking Association of America
• Heartcore Capital
• Hedia
• HelloBetter
• Hello Heart
• HelloFresh
• HeraMED
• Hercules Capital
• Heritas Capital
• Heuristic Capital
• Hevella Capital
• Highmark Health
• Highmark Interactive
• High-Tech Gründerfonds
• Higi
• Hikma Ventures
• Hinduja Group
• Hinge Health
• HITLAB
• Hiventures
• HLM Venture Partners
• HMA Capital Partners
• Holmusk
• Horizon 2020
• European Innovation Council (EIC)
• Hubble Connected
• Human API
• Humana
• Hyde Park Angels
• Hygieia
• IBB Ventures
• IBH Population Health Solutions
• iBreve
• Icon Ventures
• Idinvest Partners
• Ieso Digital Health
• iFeel Labs
• IIB Sant Pau
• Illinois Department of Healthcare and Family Services
• Illumigyn
• Illumina Ventures
• ImagineMIC™
• Insan Mulia Abditama 
• Impact Ventures UK
• IMPUTE Inc.
• Incos Invest
• Indegene
• India Edison Accelerator
• India Innovation Initiative
• Industry Ventures
• INFOR Financial 
• Information Technology Academia Collaboration (ITAC)
• InHealth Ventures
• Inito
• inMotion VR
• inne
• Innovation Skåne
• InnovHealth 
• Inova
• Insight Partners
• Insignia Ventures Partners
• Sant Pau Biomedical Research Institute (IIB Sant Pau)
• Institute of Mental Health (IMH)
• Insulet
• InsurTech.vc
• Integra Community Care Network
• Integra Partners
• Intel Capital
• Intermountain Ventures
• International Capital Management
• International Finance Corporation (IFC)
• International Medical Center Apps
• International Technology Law Association (ITechLaw)
• Invest Detroit
• Investec Ventures
• ION Crossover Partners
• IP Group
• IPD Capital
• IPOPEMA Securities
• Ironwood Pharmaceuticals
• iSeed Ventures
• iSono Health
• Itamar Medical
• Iterative Capital 
• IT-Farm
• ITOCHU
• ITOCHU Technology Ventures
• IVP
• Iwagin Business Creation Capital
• Iwagin Jigyo Souzou Capital
• iXensor
• J.P. Morgan
• JamJar Investments
• Janssen Pharmaceutica NV
• Janssen Research & Development
• January Ventures
• JAZZ Venture Partners
• Jennis
• Jianke
• Jichi Medical University
• JJDC
• JOGO Health
• Johns Hopkins HealthCare Solutions
• Johnson & Johnson
• Johnson & Johnson Innovation
• Johnson Venture Partners (JVP)
• Joint Academy
• Jolly Good
• Joy Ventures
• Joyable
• Joyance Partners
• K2 HealthVentures
• K2 Investment Partners
• Kaia Health
• Kakao Ventures
• Kamet Ventures
• Kapor Capital
• Karista
• Karolinska Institutet
• Karuna Labs
• KEGG (Kyoto Encyclopedia of Genes and Genomes)
• Keio Innovation Initiative
• Kelvi
• Kenetic Capital
• Kentucky Science and Technology Corporation (KSTC)
• Kheiron Medical Technologies
• Khosla Ventures
• Khyria
• Kicker Ventures
• Kiio
• Kima Ventures
• Kindbody
• King River Capital
• King's College London
• Kinnevik
• KiOmed Pharma
• KLAVA Innovation
• Kleiner Perkins Caufield & Byers
• Kleiner Perkins Caufield & Byers (KPCB)
• Koa Health
• Konna xyz
• KORE Digital Health Therapeutics
• Korea Advanced Institute of Science and Technology
• Korea Technology Finance 
• Korea Investment Partners
• Kormeli
• Kortex Ventures
• Koshidaka Holdings
• KTB Network
• Kurbo Health
• Kwit
• Kyma Medical Technologies
• Kyushu University
• LabQ International
• BlackRock Private Equity Partners
• Lactamo
• LactApp
• Lactation Lab
• Ladera Venture Partners
• Laguna Investment
• LAIA
• Laia 
• Laidir Foundation
• Lark Health
• Launchpad Venture Group
• Lead Edge Capital
• League of Innovators
• Leap Fitness Group
• Leaps by Bayer
• Learn Behavioral
• Learn 
• Leerink Transformation Partners
• Leksell Social Ventures
• Lemonaid Health
• LetsGetChecked
• LexisNexis Risk Solutions
• Lief Therapeutics
• LifeScan
• Life Science Innovation Fund (LSI)
• Lifeforce Capital
• Lifeline Ventures
• LifeSense Group (LSG)
• Lifestyle & Wellness Medical Center
• Lightspeed Venture Partners
• Limbix
• Linchpin Healthcare
• LionBird Ventures
• Liquid 2 Ventures
• Liriro
• Lisa Health
• LiveBetter
• Livia
• Livongo Health
• LongHash Ventures
• Louisiana Department of Health
• LRVHealth
• LSP
• LUCID
• Lucina Analytics
• Luma Womb
• LumiraDx
• LUNA-endometriose 
• Lund University
• Lux Capital
• M Venture Partners (MVP)
• M Ventures
• M12, Microsoft's Venture Fund
• Mabel
• Mae
• Magellan Health
• Magic Horizons
• Magnetic Ventures
• Mahana Therapeutics
• Mahmee
• MAIF Avenir
• Maine Technology Institute
• Maki.vc
• Mana Ventures
• Mangrove Capital Partners
• Manhattan Venture Partners
• Manipal Education and Medical Group
• MannKind 
• Manulife
• MAP Health Management
• MAPFRE
• Mass General Brigham
• Massachusetts General Hospital
• Massachusetts Institute of Technology (MIT)
• MassChallenge
• MassMutual Ventures
• Material Impact
• Materna Medical
• Maven Clinic
• Maven Ventures
• Maverick Ventures
• Maveron
• Maya Digital Health
• Mayden
• Mayo Clinic
• MBS innovation DRIVE
• McKesson Ventures
• McKinsey
• McLean Hospital
• MDLIVE
• Medical Mutual of Ohio
• Medifox Dan
• MediPeace Vietnam
• I-Medita
• MedRhythms
• MedTech Entrepreneurs
• Medtech Women
• Medtronic
• Medvest Capital
• MEEZA
• Meliora Technology
• Melon Health
• Mementor (Acquired by ResMed)
• Memorial Sloan Kettering Cancer Center (MSKCC) 
• MemorialCare Innovation Fund (MCIF)
• Menopod
• Mercer
• Merchavia
• Merck
• Merck Global Health Innovation Fund
• M Ventures
• Meridian Street Capital
• Meritech Capital Partners
• Mersey Care NHS Foundation Trust
• Meru Health
• Meta
• metaMe
• MetFlux Research
• Metrocare Services
• Metrodora Ventures
• Metronomic 
• Microsoft
• Midlands Engine Investment Fund (MEIF)
• MiLA Capital
• MiMARK
• Min Doktor
• Mindable Health
• MindBeacon Group
• Mind Cure Health
• Mindmaze
• Mindset Health
• MindWise Innovations
• MINES & Associates
• Mira
• Mirae Assets
• Mitsubishi UFJ Capital
• I Mercury Capital
• Mizuho Capital
• MJog
• MobileODT
• Mobio Technologies
• Modern Fertility
• Molbio Diagnostics
• Molten Ventures
• Monarch Medical Technologies
• Monashee Investment Management
• Monkfish Equity
• Montage Ventures
• MooDoos Investments
• Moonai
• Moonwhale Ventures
• More Provident Funds
• Morningside
• Morningside Group
• Mountain Group Partners
• MoveUp
• MTIP
• Mundi Ventures
• Mundipharma
• MUTU System
• MyAva
• My mhealth
• Myant
• MyLife ID
• Nabta Health
• Nagoya City University
• Naluri
• Nantahala Capital Management
• National Breast Cancer Foundation
• National Cancer Center (NCC)
• National Cancer Institute
• National Cancer Institute (NCI)
• National Center of Neurology and Psychiatry (NCNP)
• National Education Association (NEA)
• National Health Service (NHS)
• National Healthcare Group (NHG)
• National Heart Centre Singapore (NHCS)
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• National Institute of Mental Health
• National Institute on Aging
• National Institutes of Health (NIH)
• National Rheumatoid Arthritis Society
• National Science Foundation
• National Science Foundation (NSF)
• National Technical University of Athens (NTUA)
• Natural Cycles
• Navitus Health Solutions
• Naytal
• NCL Technology Ventures
• National Education Association (NEA)
• Nebrija University
• Nest Collaborative
• Neuberger Berman Funds
• Neuroglee Therapeutics
• NeuroMetrix
• Neurotrack
• New England-Israel Business Council (NEIBC)
• New Enterprise Associates
• New Leaf Venture Partners
• Meritain Health
• New Mexico Retiree Health Care Authority (NMRHCA)
• Newsenselab
• Newtopia
• Nex Cubed
• Next AI
• NEXT Canada
• NextGen Venture Partners
• Nexus Venture Partners
• NGP Capital
• NHL Alumni Association
• NightWare
• National Institute of Health (NIH)
• Nimble Ventures
• Nimbus Synergies
• Nina Capital
• Niramai
• Noaber
• Nokia Growth Partners
• Noom
• Nordic Brain Tech
• Nordic Eye Venture Capital
• Nori Health
• Northwell Holdings
• Norwest Venture Partners
• Novartis
• Novartis Venture Fund
• Novator Partners
• Novo Holdings
• Novo Nordisk
• NSI Ventures
• Nunaps
• NursElet
• Nuvo Group
• Oak HC/FT
• Oath Care
• Ocean Azul Partners
• OCON Healthcare
• Octopus Ventures
• Okhlahoma Health Care Authority
• Oky
• Olive Tree Capital
• Olive Tree Ventures
• Omada Health
• Omega Capital Partners
• Omidyar Technology Ventures
• Omron Corporation
• Oncology Care Home Health Specialists
• One Drop
• ONE WORLD Training & Investments
• Ontario Telemedicine
• Oova
• Openspace Ventures
• Operator Partners
• Optum Ventures
• Opus Growth
• Oratel Diagnostics
• OrbiMed
• Ordinary Folk
• Örebro University
• Orexo
• Orion
• Orreco
• OSF Ventures
• Ospedale Malcantonese (OSCAM)
• Otsuka America
• Otsuka Health Solutions
• Otsuka Pharmaceutical 
• Oula Health
• OurCrowd
• Outcomes fund
• Ovia Health
• Ovira
• Ovulai
• Ovulation Calculator
• Owl Health
• Owl Ventures
• Oxeon
• Oxford Academic Health Science Network
• Oxford University
• Ozential Digital Therapeutics
• PaceZero Capital Partners
• Pachamama
• Pacific Health Ventures
• Pallasite Ventures
• Palo Alto Medical Foundation
• Parasail Health
• Parentlane
• Parian Global Management
• Partum Health
• Pathology Asia
• Payor Logic
• PayPal
• PBJ Capital
• Pear Therapeutics
• Pegasus Tech Ventures
• Pepapp
• Peramare
• Perceptive Advisors
• PeriGen
• Pfizer
• PFM Health Sciences
• Phenomenal Women's Health
• Phenomenelle Angels
• Philips
• Phoenix Insurance
• Physera
• pi Ventures
• Picus Capital
• Pilot House
• Pixvana
• Plackal Tech 
• Plan International
• Playwing
• Plug and Play Tech Centre
• Polaris Partners
• Polytech Ventures
• Pomelo Care
• Pond Capital
• Pontifax Venture Capital
• Portland Seed Fund
• PreemieWorld
• PregnaScan
• Premera Blue Cross
• Presence Capital
• Primary Health Care Corporation (PHCC)
• Prima-Temp
• Prime Therapeutics
• Prime Venture Partners
• Prism Healthcare
• Privia Health
• Privitar
• Proactive for her
• Prodeko Ventures
• Prognos Health
• Progyny
• Proov
• Propeller Health
• Prority Health
• Protocol Labs
• Prototron
• Providence Health & Services
• Providence Ventures
• Pruksa Group
• PsyInnovations
• pumpspotting
• Punchbowl
• Pura Vida Investments
• Purdue University
• PureTech Health
• QBIC - Qatar Business Incubation Center
• Qiming Venture Partners
• QUAD Investment Management
• Quadrille Capital
• Qualcomm Life
• Quiver Tree Investments
• Qure Ventures
• Raiing Medical
• Rally Health
• Raydiant Oximetry
• Reaktor Ventures
• Red One Medical
• RedBrick Health
• Redbrick
• Redicare Control
• Redmile Group
• Redox
• Reflectance Medical
• Region Östergötland
• Region Skåne
• Renalis
• Renovia
• Research Society for The Study of Diabetic in India (RSSDI)
• ResMed
• Resolute Ventures
• Restore Health
• Rethink Impact
• Revelation Partners
• Revive Therapeutics
• Revon Systems
• Rhia Ventures
• RHL Ventures
• RhythmiaBreath
• RISE (Research Institutes of Sweden)
• Ro
• Roblox
• Roche
• Roche Diabetes Care
• Roche Diagnostics
• RoX Health
• Royal Society of Medicine 
• RRE Ventures
• RS Investments
• Russell Siegelman
• S.R. One
• Saama Capital
• Safar Partners
• Safeguard Scientifics
• Sage Capital Partners
• Sagentia Innovation
• Saisei Ventures
• Saison Ventures
• Salem Partners
• SalesForce
• Salumedia
• Samsung
• Samsung Health
• Sandoz
• Sano
• Sanofi
• Sanofi Ventures
• Santora Nakama
• SAP
• Sapiens Ventures
• Sapphire Ventures
• Sarissa Capital
• Sarjan Health
• SBI Investment 
• Scale Capital
• Schoolhouse Partners
• Scientific Federation
• Scientific Med
• SD Venture
• Seashore Solutions
• Sectoral Asset Management
• SEED Capital 
• SeedtoB Capital
• SelfBack
• Sennheiser
• Senseonics
• Seoul National University Bundang Hospital
• Sequoia Capital
• Sequoia India
• Sera Prognostics
• Seraph Venture
• Serena Ventures
• Seroba Life Sciences
• Servier
• Sevenlogics
• SGInnovate
• Shanda Group
• Sharecare
• Shareholder Value Management
• She Loves Tech
• Shinsei Bank
• Shinsei Corporate Investment
• Shionogi
• Shire Pharmaceuticals
• Sidekick Health
• Sidgetop Health
• Signant Health
• Silicon Valley Bank
• Silver Cloud Health
• Silver Lake
• Simon & Schuster
• Simplyhealth
• Sivan Innovation
• Skånsk Innovationskraft
• SMBC Venture Capital
• Social Starts
• Softbank 
• SoftBank Vision Fund
• SoftTech
• Solera Health
• SOMA Breath
• SOMPO Digital Lab
• Sompo Holdings
• Sonormed
• Sonova Group
• Sony Innovation Fund
• SOSV
• Sozo Ventures
• SparkLabs
• Sparrow Ventures
• Speak AI
• Spice Capital
• Spring Mountain Capital
• Springboard
• Springbuk
• SR One
• Srirakshaa Healthcare
• Stanford Technology Ventures Program
• Stanford University
• Stanford University Mind & Body Lab
• Stanford University School of Medicine
• Stanley Park Ventures
• Starting Line
• Startmate
• StartUp Health
• Startupbootcamp Digital Health Berlin
• StartX Fund
• Stateline Angels
• StayWell
• SteadySense
• Steelcase
• SteelSky Ventures
• SternAegis Ventures
• Stewart Greenebaum
• Stifel GMP
• Storka
• Storm Ventures
• Stress Point Health
• Stripes
• Sumitomo Dainippon Pharma
• Sumitomo Mitsui Trust Investment
• Summer VC
• Summit Partners
• Summit Reinsurance Services
• SureHire
• Susmed
• SVB Ventures
• SVC
• Sway Ventures
• Swedish Breast Cancer Association
• Sweet Capital
• Sweetch
• Swing Therapeutics
• Swiss Healthcare Startups (SHS)
• Swiss Re
• Symphony Ventures
• Syrona Health
• Tal Capital
• TALi Health
• Tamtris Web Services
• Target
• Target Global
• Tech Up For Women
• Tech4Eva
• Techammer
• Techstars
• Teijin
• Teladoc Health
• TELUS Ventures
• Tempdrop
• Tennessee Department of Intellectual and Developmental Disabilities (DIDD)
• Terumo
• Texas HALO Fund
• The Aplastic Anemia & MDS International Foundation
• The Body Literacy Collective
• The Female Health Hub
• The Harris Center for Mental Health and IDD
• The Learning Corp
• The Lily Project
• The Pelvic Expert
• Regents of the University of California
• The Research Foundation for The State University of New York 
• The Shoko Chukin Bank
• The University of Texas Health Science Center at Houston (UTHealth)
• The Venture Reality Fund
• The Vertical Group
• Thimble Point
• Think Bigger Capital
• Think.Health
• Tia
• Tiger Global Management
• Tilak Healthcare
• Titan Capital  
• Tokyo Century
• Tooly Tech
• TOYOSHIMA
• Trend Forward Capital
• TrialSpark
• Trinity Capital
• Triumf Health
• TruDiary
• True Ventures
• Trustbridge
• TT Capital Partners
• Turnaround Health
• Tutorify
• U.S. Venture Partners
• Ubicom Holdings
• UCB
• UCI Health
• Uncork Capital
• Union Square Ventures
• Unique Nutrition Solutions
• United Healthcare
• United Nations University International Institute for Global Health (UNU-IIGH)
• UnityPoint Health Ventures
• Universal Music Group
• University Hospitals
• University of Applied Sciences and Arts of Southern Switzerland (SUPSI)
• University of California
• University of Missouri
• University of Nebraska Medical Center 
• University of New York
• University of Pennsylvania
• University of Sydney
• University of Washington
• Unum
• UpLift Health
• Upright Technologies
• Uvi Health
• VA Palo Alto Health Care System 
• Validic
• VCapital 
• Vectr Ventures
• Vectura
• Veera Health 
• Velmio
• Venrock
• Venture Catalysts
• Venture Kick
• Venture Partners
• Vicore Pharma
• Victorum Capital Club
• Vida Health
• Vigo
• Virgin Pulse
• Virta Health
• Virtue Health
• Vitadio
• Vitality Group
• Vivant
• Vivid Vision
• VNV Global
• Voluntis
• VSP Vision Care
• Wachanga
• Wake Forest University
• Wakestream Ventures
• Walking Ventures
• Wallgreens
• Wanxiang America Corporation
• Watkins-Conti Products
• Wavemaker 360
• Waypoint Health Innovations
• Wayra
• WEA Trust
• Webb Investment Network
• Weill Cornell University
• NYP Hospital
• Vanderbilt University Medical Center
• Welkin Health
• WellBe
• Welldoc
• WellDyne
• Wellington Management
• Wellington Partners
• Wells Fargo
• Wellspan Health
• Wellthy Therapeutics
• Welltoc
• Werth Family Investment Associates
• Western Development Commission
• White Fund
• Wildflower Brands
• Wildflower Health
• Willis Towers Watson
• Willow
• Wings Fund
• Wisconsin Investment Partners
• Wisdom LLP
• Wise Health System
• Withings
• Woebot Health
• Wolfpack Digital
• Women In Bio
• Women in Data
• WITI (Women in Technology International)
• Women of Wearables (WoW)
• Women's Health Connecticut  
• WomenUP
• Wonju Severance Christian Hospital
• Woom
• Workday Ventures
• Workit Health
• WP Global Partners
• WPS Health Insurance
• WRF Capital
• Wrnch (Acquired by Hinge Health)
• WVU Medicine
• Xbird
• Xpectives.Health
• Y Combinator
• Yesmom
• Youturn Health
• Yozma
• Ysios Capital
• Zaffre Investments
• Zaya Care
• Zendesk
• ZENworks
• Zero Mothers Die
• Zillion
• Zinc
• Zoie Health
• Zoll Medical
• Zuellig Pharma
• Zyus

Methodology